Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA
Rhea-AI Summary
Agios (Nasdaq: AGIO) said it will pursue U.S. accelerated approval for mitapivat in sickle cell disease after a March 31, 2026 pre-sNDA meeting with the FDA. The company has submitted a proposed confirmatory trial protocol and plans to file an sNDA in the coming months while working to align with FDA on trial design.
Agios said the proposed confirmatory trial uses a different primary endpoint informed by RISE UP data, and current planning expects operating expense guidance to remain approximately flat versus 2025.
Positive
- FDA recommended submission of a confirmatory trial proposal (March 31, 2026)
- Company submitted proposed confirmatory trial protocol to FDA for review
- Plans to submit mitapivat sNDA for sickle cell disease in coming months
- Operating expense guidance expected to remain approximately flat versus 2025
Negative
- U.S. approval is contingent on a confirmatory trial to convert accelerated approval
- Ongoing need to align with FDA on trial design could delay final approval timing
Market Reaction – AGIO
Following this news, AGIO has gained 17.53%, reflecting a significant positive market reaction. Our momentum scanner has triggered 47 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $34.80. This price movement has added approximately $304M to the company's valuation. Trading volume is very high at 3.0x the average, suggesting strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
Among close biotech peers, only DNLI showed momentum in scanners, up 6.08% with no news, while others had modest mixed moves. With AGIO up 0.61% and limited peer momentum, trading appears more company-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 02 | Regional drug approval | Positive | -3.4% | PYRUKYND approved for adult thalassemia patients in the United Arab Emirates. |
| Feb 12 | Earnings and update | Positive | +1.3% | Q4 and FY 2025 results with PYRUKYND revenue growth and $1.2B cash. |
| Jan 26 | Earnings call notice | Neutral | +1.0% | Announcement of timing for Q4 and full-year 2025 results webcast. |
| Jan 12 | Strategy outlook | Positive | -0.3% | Outlined 2026 priorities and projected PK activation franchise peak sales potential. |
| Jan 05 | Conference presentation | Neutral | +1.0% | Planned presentation at the 44th J.P. Morgan Healthcare Conference. |
Regulatory and strategic positives have not consistently translated into positive next-day moves, with several approvals and milestones followed by mild declines.
Recent news highlights Agios’ steady push in rare hematologic diseases. In January–March 2026, the company outlined 2026 priorities, gained UAE approval for PYRUKYND in thalassemia, and confirmed strong $1.2B cash with growing PYRUKYND revenue. Despite these positives, price reactions were mixed, including a -3.41% move after UAE approval. Today’s accelerated-approval path for mitapivat in sickle cell disease extends this regulatory and portfolio-expansion narrative.
Regulatory & Risk Context
An automatic shelf registration on Form S-3ASR filed on 2026-02-12 is effective, allowing Agios to offer debt, equity, warrants and units over time. No takedowns have been recorded yet (usage_count: 0). Proceeds are designated for general corporate purposes, including R&D, commercialization, and potential acquisitions.
Market Pulse Summary
The stock is surging +17.5% following this news. A strong positive reaction aligns with Agios’ ongoing pivot toward hemoglobinopathies and regulatory progress. The pre-sNDA FDA meeting and plan to seek U.S. accelerated approval for mitapivat in sickle cell disease extend prior milestones such as PYRUKYND growth and regional approvals. Investors have a confirmed S-3ASR shelf and recent insider tax-related sales to monitor when assessing how durable any move might be.
Key Terms
accelerated approval regulatory
snda regulatory
new drug application regulatory
phase 2 medical
phase 3 medical
endpoint medical
pyruvate kinase medical
AI-generated analysis. Not financial advice.
- Company has already submitted proposed confirmatory trial for FDA review, as required under accelerated approval pathway
- Company plans to submit mitapivat sNDA in sickle cell disease in the coming months, and is actively working with FDA to achieve alignment on confirmatory trial required for submission
CAMBRIDGE, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that it will pursue U.S. accelerated approval for mitapivat, an oral pyruvate kinase (PK) activator, in sickle cell disease, following completion of its pre-supplemental New Drug Application (sNDA) meeting with the U.S. Food and Drug Administration (FDA).
The purpose of the pre-sNDA meeting was to present the data from the mitapivat RISE UP clinical program in sickle cell disease, including both the Phase 2 and Phase 3 trials. Based on the discussion, the FDA recommended submission of a proposal for a confirmatory clinical trial to support U.S. accelerated approval of mitapivat. The FDA’s accelerated approval pathway expedites the availability of medicines that can fill a medical need for a serious condition, with the requirement of a confirmatory clinical trial to convert to a traditional approval.
“Our engagements with the FDA continue to underscore both the unmet need in sickle cell disease and the importance of expeditiously advancing new treatment options for patients living with this complex, debilitating, and deadly disease,” said Sarah Gheuens, M.D., Ph.D., Chief Medical Officer and Head of R&D, Agios. “The clinically meaningful benefits observed in the RISE UP clinical program, combined with our ongoing, constructive, and collaborative dialogue with the FDA, reinforce our confidence in mitapivat’s potential in sickle cell disease. We are focused on advancing mitapivat as rapidly as possible with the rigor required for potential U.S. accelerated approval.”
Agios has already submitted its proposal for the required confirmatory clinical trial to the FDA for review. This proposal incorporates a primary endpoint that is different from those in the RISE UP clinical program and is informed by both analyses of RISE UP data and discussions with the FDA. Based on current planning assumptions, the proposed confirmatory clinical trial is not expected to change the company’s previously issued operating expense guidance, which remains approximately flat compared to 2025.
The company plans to submit a mitapivat sNDA for sickle cell disease in the coming months, and is actively working with the FDA to achieve alignment on the confirmatory clinical trial required for submission.
About Sickle Cell Disease
Sickle cell disease is a rare, inherited blood disorder caused by the production of abnormal hemoglobin that disrupts the ability of red blood cells to carry oxygen throughout the body. As a result, red blood cells become rigid and sickle-shaped, causing deformation of red blood cell membranes and the premature death of the cells. These effects lead to chronic hemolytic anemia, vaso-occlusion, and a cascade of severe and life-threatening complications, including long-term damage to the lungs, kidneys, and cardiovascular system. Due to its physical toll, sickle cell disease imposes a profound burden on patients and their families, marked by increased healthcare needs and early mortality.
About Mitapivat in Sickle Cell Disease
Mitapivat, an oral pyruvate kinase (PK) activator, is designed to enhance the process by which red blood cells produce energy. This approach has the potential to improve red blood cell health by increasing ATP levels to support increased energy demands and lowering levels of a molecule called 2,3-diphosphoglycerate (2,3-DPG). In sickle cell disease, increased stress on red blood cells results in elevated levels of 2,3-DPG, which raises the likelihood that red blood cells develop the abnormal “sickle” shape that triggers vaso-occlusive crises.
About the RISE UP Phase 3 Trial Topline Results
The global RISE UP Phase 3 trial (NCT05031780) is evaluating the efficacy and safety of mitapivat in sickle cell disease patients aged 16 years or older, representative of the global population. The trial consisted of a 52-week, double-blind, randomized, placebo-controlled phase, in which 207 participants were randomized 2:1 to receive oral mitapivat (100 mg) twice daily (n=138) or matched-placebo (n=69). Upon completion, participants could transition into an open-label extension phase where all receive mitapivat.
To comprehensively evaluate objective measures of hemolysis alongside other clinically relevant outcomes in sickle cell disease, the double-blind phase of RISE UP included two primary endpoints – hemoglobin response and annualized rate of sickle cell pain crises – as well as five key secondary endpoints measuring hemoglobin concentration, indirect bilirubin (a biomarker of hemolysis), patient-reported fatigue, hospitalizations for sickle cell pain crises, and percent reticulocyte levels (a biomarker of erythropoiesis).
Mitapivat demonstrated a statistically significant improvement compared to placebo in the study’s primary endpoint of hemoglobin response, defined as a ≥1.0 g/dL increase from baseline in average hemoglobin concentration from Week 24 through Week 52. Although mitapivat showed a reduction in the annualized rate of sickle cell pain crises compared with placebo, this primary endpoint did not reach statistical significance.
Patients receiving mitapivat who achieved the hemoglobin response primary endpoint had clinically meaningful improvements in hemoglobin concentration. These patients also experienced other clinically meaningful benefits, including reductions in pain crises and related hospital visits, along with improvements in fatigue.
The safety profile was favorable and consistent with prior mitapivat trials in sickle cell disease. The 52-week double-blind phase was completed by
About Agios: Fueled by Connections to Transform Rare Diseases™
At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities – collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit www.agios.com and follow us on LinkedIn and X.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of mitapivat; Agios’ expectations for its submission of a sNDA and the review of such sNDA by the FDA; Agios’ commercial expectations for mitapivat; and the potential benefits of Agios’ strategic plans and focus. The words “anticipate,” “expect,” “goal,” “hope,” “milestone,” “plan,” “potential,” “possible,” “strategy,” “will,” “vision,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios’ current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios’ product candidates will successfully continue. There can be no guarantee that any positive developments in Agios’ business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including, without limitation: risks and uncertainties related to the impact of pandemics or other public health emergencies to Agios’ business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Agios’ results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios’ ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios’ ability to establish and maintain key collaborations; uncertainty regarding any royalty payments related to the sale of its oncology business or any milestone or royalty payments related to its in-licensing of AG-236, and the uncertainty of the timing of any such payments; uncertainty of the results and effectiveness of the use of Agios’ cash and cash equivalents; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Agios’ public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contacts:
Investor Contact
Morgan Sanford, Vice President, Investor Relations
Agios Pharmaceuticals
morgan.sanford@agios.com
Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
eamonn.nolan@agios.com
FAQ
What did Agios announce about mitapivat and accelerated approval on March 31, 2026 (AGIO)?
Has Agios submitted the confirmatory clinical trial proposal for mitapivat (AGIO)?
When will Agios file the mitapivat sNDA for sickle cell disease (AGIO)?
What does FDA accelerated approval mean for mitapivat (AGIO)?
Will the confirmatory trial change Agios' 2026 operating expense guidance (AGIO)?
What are the main risks to mitapivat approval timing after Agios' pre-sNDA meeting (AGIO)?
